Search
Morniflumate
go.drugbank.com/drugs/DB09285InvestigationalMorniflumate is a non-steroidal anti-inflammatory drug with antipyretic properties. It is the morpholinoethyl ester of niflumic acid . In one study, post morniflumate ingestion, physical examination and clinical symptoms of those with br...
Votucalis
go.drugbank.com/drugs/DB05032InvestigationalrEV131 is in development for allergic rhinitis, asthma and several inflammatory eye diseases. It is a topically delivered small protein that acts as an anti-inflammatory agent.
Multipotent adult arogenitor cells
go.drugbank.com/drugs/DB15742InvestigationalAfter administration, the cells are cleared from the body over time. Currently, MultiStem is being investigated against neurological, inflammatory, immune, and cardiovascular diseases and conditions.
ATX-101
go.drugbank.com/drugs/DB05780InvestigationalATX-101 demonstrates a relative selectivity for fat over other tissues.
CYP-001
go.drugbank.com/drugs/DB15739InvestigationalThese cells have advantage over other MSCs because a large amount can be obtained from a single healthy blood donor, negating the risks from donor-and expansion dependent variability.
IMM101
go.drugbank.com/drugs/DB15851ExperimentalAs of July 2020, researchers from the Ottawa Hospital and Queen’s University, in partnership with the Canadian Cancer Society-funded Canadian Cancer Trials Group (CCTG), are conducting a trial in over
Human cord blood hematopoietic progenitor cell
go.drugbank.com/drugs/DB11054ApprovedThe unrelated donor transplant setting has several advantages over related donor transplant and bone marrow transplantation; it allows shorter time to transplant and tolerance of 1–2 human leukocyte antigen
Bevacizumab
go.drugbank.com/drugs/DB00112ApprovedInvestigational[L45793,L43130] For over a decade, bevacizumab was also used off-label by intravitreal injection to treat neovascular (wet) age-related macular degeneration and other retinal conditions, repackaged from
Ruxolitinib
go.drugbank.com/drugs/DB08877ApprovedInvestigational[A229708] Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed.
Pravastatin
go.drugbank.com/drugs/DB00175ApprovedInvestigationalPravastatin is the 6-alpha-hydroxy acid form of mevastatin. Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug....